Iovance Biotherapeutics’s Amtagvi is now the first FDA-approved treatment based on type of cell called a tumor-infiltrating lymphocyte. The regulatory nod in advanced melanoma also makes Amtagvi the first cell therapy approved for treating a solid tumor.
Medical experts dissect critical strategies for monitoring for potential adverse events with bispecific antibodies in a comprehensive panel discussion.
A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy.
NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.